Judith A Fox

Title: Judith A. Fox: Innovator in Immunotherapy

Introduction

Judith A. Fox is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of immunotherapy, particularly through her innovative binding proteins. With a total of 7 patents to her name, her work has the potential to impact the treatment of various cancers.

Latest Patents

One of Judith's latest patents involves bispecific CD33 and CD3 binding proteins. These binding proteins are designed to specifically target human CD33, which is crucial for developing therapies for conditions such as acute myeloid leukemia (AML). The patent describes bispecific tandem diabodies that bind to CD33, highlighting their potential uses in immunotherapy for CD33-related cancers and diseases.

Career Highlights

Throughout her career, Judith has worked with notable companies such as Danisco US Inc. and Amphivena Therapeutics, Inc. Her experience in these organizations has allowed her to refine her expertise in the development of innovative therapeutic solutions.

Collaborations

Judith has collaborated with esteemed colleagues, including Volker Schellenberger and Kristina Ellwanger. These partnerships have further enhanced her research and development efforts in the field of immunotherapy.

Conclusion

Judith A. Fox is a trailblazer in the realm of immunotherapy, with a focus on developing binding proteins that can significantly improve treatment outcomes for patients with acute myeloid leukemia and other related conditions. Her contributions to the field are invaluable and continue to pave the way for future innovations.